- Home
- ALAB vs BMRN Comparison
ALAB vs BMRN Comparison
Compare ALAB & BMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALAB
- BMRN
- Stock Information
- Founded
- ALAB 2017
- BMRN 1996
- Country
- ALAB United States
- BMRN United States
- Employees
- ALAB N/A
- BMRN N/A
- Industry
- ALAB
- BMRN Biotechnology: Pharmaceutical Preparations
- Sector
- ALAB
- BMRN Health Care
- Exchange
- ALAB NYSE
- BMRN Nasdaq
- Market Cap
- ALAB 15.0B
- BMRN 11.3B
- IPO Year
- ALAB 2024
- BMRN 1999
- Fundamental
- Price
- ALAB $128.87
- BMRN $58.81
- Analyst Decision
- ALAB Strong Buy
- BMRN Buy
- Analyst Count
- ALAB 15
- BMRN 23
- Target Price
- ALAB $104.71
- BMRN $93.73
- AVG Volume (30 Days)
- ALAB 5.2M
- BMRN 1.7M
- Earning Date
- ALAB 08-05-2025
- BMRN 08-04-2025
- Dividend Yield
- ALAB N/A
- BMRN N/A
- EPS Growth
- ALAB N/A
- BMRN 152.82
- EPS
- ALAB 0.26
- BMRN 2.71
- Revenue
- ALAB $490,474,000.00
- BMRN $2,950,227,000.00
- Revenue This Year
- ALAB $80.73
- BMRN $12.27
- Revenue Next Year
- ALAB $28.94
- BMRN $9.99
- P/E Ratio
- ALAB $504.33
- BMRN $21.74
- Revenue Growth
- ALAB 200.19
- BMRN 19.36
- 52 Week Low
- ALAB $36.22
- BMRN $52.93
- 52 Week High
- ALAB $147.39
- BMRN $94.85
- Technical
- Relative Strength Index (RSI)
- ALAB N/A
- BMRN 54.48
- Support Level
- ALAB N/A
- BMRN $57.58
- Resistance Level
- ALAB N/A
- BMRN $60.43
- Average True Range (ATR)
- ALAB 0.00
- BMRN 1.41
- MACD
- ALAB 0.00
- BMRN 0.06
- Stochastic Oscillator
- ALAB 0.00
- BMRN 58.99
About ALAB ASTERA LABS INC
Astera Labs Inc designs and delivers semiconductor-based connectivity solutions for cloud and AI infrastructure. Its Intelligent Connectivity Platform integrates semiconductor technology, microcontrollers, sensors, and software to enhance performance, scalability, and data management. The company offers products such as integrated circuits (ICs), boards, and modules, catering to hyperscalers and system OEMs. The company's solutions focus on data, network, and memory management in AI-driven platforms.
About BMRN BioMarin Pharmaceutical Inc.
BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments aimed at addressing complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria (PKU), hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development.